Table 4.
Univariate analysis of predictive molecular markers for lymph node metastasis n (%)
| Lymph node metastasis | Presence | Absence | P value |
| Microsatellite instability | 0.412 | ||
| MSS | 89 (90.8) | 820 (90.0) | |
| MSI-L | 1 (1.0) | 30 (3.3) | |
| MSI-H | 8 (8.2) | 61 (6.7) | |
| hMLH1 | 0.703 | ||
| Negative | 5 (7.4) | 43 (6.2) | |
| Positive | 63 (92.6) | 653 (93.8) | |
| p53 | 0.773 | ||
| Negative | 59 (60.8) | 592 (62.3) | |
| Positive | 38 (39.2) | 358 (37.7) | |
| EGFR overexpression | 0.001 | ||
| Negative | 55 (77.5) | 558 (90.1) | |
| Positive | 16 (22.5) | 61 (9.9) | |
| HER2 overexpression | 0.084 | ||
| Negative | 33 (84.6) | 263 (71.7) | |
| Positive | 6 (15.4) | 104 (28.3) |
MSS: Microsatellite stable; MSI-L: Microsatellite instability-low; MSI-H: Microsatellite instability-high; hMLH1: Human mutL homolog 1; EGFR: Epidermal growth factor receptor; HER2: Human epidermal growth factor receptor 2.